Cargando…
Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278422/ https://www.ncbi.nlm.nih.gov/pubmed/37342256 http://dx.doi.org/10.1177/17588359231182232 |
| _version_ | 1785060483350396928 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10278422 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102784222023-06-20 Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer Ther Adv Med Oncol Corrigendum SAGE Publications 2023-06-16 /pmc/articles/PMC10278422/ /pubmed/37342256 http://dx.doi.org/10.1177/17588359231182232 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Corrigendum Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer |
| title | Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer |
| title_full | Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer |
| title_fullStr | Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer |
| title_full_unstemmed | Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer |
| title_short | Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer |
| title_sort | corrigendum to clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278422/ https://www.ncbi.nlm.nih.gov/pubmed/37342256 http://dx.doi.org/10.1177/17588359231182232 |